Cargando…

Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer

(1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced breast cancer is limited. (2) Methods: Patients’...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellato, Daniel, Thabane, Marroon, Eichten, Caitlin, Delea, Thomas E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903278/
https://www.ncbi.nlm.nih.gov/pubmed/33466914
http://dx.doi.org/10.3390/curroncol28010051
_version_ 1783654702344306688
author Stellato, Daniel
Thabane, Marroon
Eichten, Caitlin
Delea, Thomas E.
author_facet Stellato, Daniel
Thabane, Marroon
Eichten, Caitlin
Delea, Thomas E.
author_sort Stellato, Daniel
collection PubMed
description (1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced breast cancer is limited. (2) Methods: Patients’ and physicians’ preferences for treatments for HR+/HER2−, pre-/peri-menopausal advanced breast cancer were assessed by an online discrete choice experiment (DCE). Treatment alternatives were characterized by seven attributes regarding dosing, efficacy, and toxicities, with levels corresponding to those for ribociclib plus a non-steroidal aromatase inhibitor (NSAI), NSAI, and tamoxifen. For patients, impacts of advanced breast cancer on quality of life (QOL) and ability to work/perform activities of daily living also were assessed. Patients were recruited by a Canadian breast cancer patient advocacy group through email and social media. Physicians were recruited by email. (3) Results: Among 118 patients starting the survey, 23 completed ≥ 1 DCE question (19%). Among 271 physicians who were sent the e-mail invitation, 21 completed ≥ 1 DCE question (8%). For both patients and physicians, the increased probability of remaining alive and without cancer progression over 2 years was the most important attribute. A treatment with attributes consistent with ribociclib plus NSAI was chosen by patients and physicians in 70% and 88% of the time, respectively. A substantial proportion of patients reported worrying about future diagnostic tests and their cancer getting worse; (4) Conclusions: Canadian patients and physicians are generally concordant in preference for advanced breast cancer treatments, preferring ribociclib plus NSAI to other options.
format Online
Article
Text
id pubmed-7903278
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79032782021-02-25 Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer Stellato, Daniel Thabane, Marroon Eichten, Caitlin Delea, Thomas E. Curr Oncol Article (1) Background: Past research suggests that patients with advanced breast cancer prefer treatments with improved clinical outcomes and lower risk of side effects. Evidence on preferences of Canadian patients and physicians for treatments for advanced breast cancer is limited. (2) Methods: Patients’ and physicians’ preferences for treatments for HR+/HER2−, pre-/peri-menopausal advanced breast cancer were assessed by an online discrete choice experiment (DCE). Treatment alternatives were characterized by seven attributes regarding dosing, efficacy, and toxicities, with levels corresponding to those for ribociclib plus a non-steroidal aromatase inhibitor (NSAI), NSAI, and tamoxifen. For patients, impacts of advanced breast cancer on quality of life (QOL) and ability to work/perform activities of daily living also were assessed. Patients were recruited by a Canadian breast cancer patient advocacy group through email and social media. Physicians were recruited by email. (3) Results: Among 118 patients starting the survey, 23 completed ≥ 1 DCE question (19%). Among 271 physicians who were sent the e-mail invitation, 21 completed ≥ 1 DCE question (8%). For both patients and physicians, the increased probability of remaining alive and without cancer progression over 2 years was the most important attribute. A treatment with attributes consistent with ribociclib plus NSAI was chosen by patients and physicians in 70% and 88% of the time, respectively. A substantial proportion of patients reported worrying about future diagnostic tests and their cancer getting worse; (4) Conclusions: Canadian patients and physicians are generally concordant in preference for advanced breast cancer treatments, preferring ribociclib plus NSAI to other options. MDPI 2021-01-14 /pmc/articles/PMC7903278/ /pubmed/33466914 http://dx.doi.org/10.3390/curroncol28010051 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stellato, Daniel
Thabane, Marroon
Eichten, Caitlin
Delea, Thomas E.
Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title_full Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title_fullStr Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title_full_unstemmed Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title_short Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2− Advanced Breast Cancer
title_sort preferences of canadian patients and physicians for treatment of hr+/her2− advanced breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903278/
https://www.ncbi.nlm.nih.gov/pubmed/33466914
http://dx.doi.org/10.3390/curroncol28010051
work_keys_str_mv AT stellatodaniel preferencesofcanadianpatientsandphysiciansfortreatmentofhrher2advancedbreastcancer
AT thabanemarroon preferencesofcanadianpatientsandphysiciansfortreatmentofhrher2advancedbreastcancer
AT eichtencaitlin preferencesofcanadianpatientsandphysiciansfortreatmentofhrher2advancedbreastcancer
AT deleathomase preferencesofcanadianpatientsandphysiciansfortreatmentofhrher2advancedbreastcancer